153 results
Page 3 of 8
8-K
EX-99.1
840ai28 sf
9 Dec 21
Other Events
8:05am
8-K
EX-99.1
xlqqelwb9nh0y3a
18 Nov 21
Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA
7:40am
8-K
EX-99.1
0u70n0g9xucw 1v29o
3 Nov 21
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates
4:05pm
8-K
EX-99.1
cdpfsu4q7kz
4 Oct 21
Other Events
8:40am
8-K
EX-99.1
cfytrvi6tssf27otbn
9 Aug 21
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates
8:10am
S-3ASR
w3pidkhl9bzym op13
28 May 21
Automatic shelf registration
4:19pm
8-K
EX-99.1
ttur961xkrj
13 May 21
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
8:25am
8-K
EX-99.1
9vukj 345cg4v49
10 May 21
Results of Operations and Financial Condition
8:40am
8-K
EX-99.1
491oeppt9kj 6gp3j3mo
24 Feb 21
Results of Operations and Financial Condition
8:40am
8-K
EX-99.1
119u7jse qh6tn
21 Jan 21
Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery
8:40am
8-K
EX-99.1
6baei2vq8p4undv
11 Jan 21
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program
8:40am
8-K
EX-99.2
k5ld5kqb
11 Jan 21
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program
8:40am
8-K
EX-99.1
o236ruk7 gvbk45
13 Nov 20
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain
8:40am